Boston Scientific Acquires Devoro Medical

SARIA Acquires Devro for £540 Million

November 27, 2022

Food & Beverage

SARIA SE & Co. KG has agreed to acquire Scotland-based collagen casing maker Devro for £540 million. The purchase will combine SARIA’s existing casing activities with Devro’s global manufacturing footprint to broaden product offerings, increase scale and accelerate long-term sustainable growth.

Surmodics Acquires Vetex Medical Limited

July 6, 2021

Medical Devices

Surmodics, Inc. (NASDAQ: SRDX) acquired Galway-based Vetex Medical Limited to expand its thrombectomy portfolio with the ReVene Thrombectomy Catheter. The deal included an upfront payment of $39.9 million and up to $7 million in additional milestone payments (with $3.5 million guaranteed), giving Surmodics a second FDA 510(k)-cleared mechanical thrombectomy device and IP to accelerate its thrombectomy platform development.

Boston Scientific Agrees to Acquire Bolt Medical

January 8, 2025

Medical Devices

Boston Scientific Corporation entered into a definitive agreement to acquire Bolt Medical, Inc., developer of an intravascular lithotripsy (IVL) laser-based platform for treating calcified coronary and peripheral artery disease. The deal includes an upfront payment of about $443 million for the 74% stake Boston Scientific does not already own, plus up to $221 million tied to regulatory milestones.

Thermo Fisher Scientific to Acquire Clario Holdings for $8.875 Billion

October 29, 2025

Healthcare Services

Thermo Fisher Scientific has announced an agreement to buy Clario Holdings, a provider of digital endpoint data solutions for clinical trials, for $8.875 billion in cash plus up to $400 million in earnout payments. The acquisition is expected to close by mid-2026, subject to regulatory approvals, and will expand Thermo Fisher’s digital capabilities for pharma and biotech clinical research.

Boston Scientific Acquires BTG plc

August 19, 2019

Medical Devices

Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal

January 16, 2026

Healthcare Services

Boston Scientific signed a definitive agreement to acquire Penumbra, Inc. for about $14.5 billion (enterprise value) in a cash-and-stock transaction. The deal is intended to expand Boston Scientific’s cardiovascular franchise and create a scaled position in mechanical thrombectomy and adjacent neurovascular markets, and is expected to close in 2026 subject to shareholder and regulatory approvals.